{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T19:18:50Z","timestamp":1783451930670,"version":"3.55.0"},"reference-count":37,"publisher":"Bioscientifica","issue":"1","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":183,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["journals.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>Mitotane is the standard therapy for advanced pediatric adrenocortical carcinoma (pACC). With improving survival, treatment-related long-term side effects and their impact on everyday functioning are becoming increasingly relevant. This multicenter pilot study provides first insights into this underexplored topic and lays the groundwork for future prospective investigations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design and methods<\/jats:title>\n                    <jats:p>Caregivers of children with pACC treated with mitotane completed an online questionnaire. Based on these retrospective caregiver-reported data, treatment-related side effects and growth parameters were assessed. Using two validated instruments \u2013 Child and Adolescent Scale of Participation (CASP) and Strengths and Difficulties Questionnaire (SDQ) \u2013 caregivers rated functional participation and behavioral outcomes. We classified patients according to ongoing versus completed mitotane therapy and compared them with a sibling control group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The cohort included 24 children with pACC from eight countries, predominantly with advanced tumors (stage III\u2013IV: 66.7%, median age: 7.4 years, 41.7% females). Half had completed mitotane therapy, and half were still receiving it. Most patients experienced relevant side effects, with adrenal insufficiency being the most frequent ongoing limitation. Patients on ongoing mitotane therapy showed reduced functional participation and more pronounced behavioral difficulties, whereas those who had completed therapy had outcomes comparable to their siblings.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The findings of this pilot study suggest temporary impairments in functional participation and psychosocial behavior during mitotane treatment, with improvement after therapy completion. In contrast, endocrine sequelae, particularly adrenal insufficiency, may persist beyond treatment. These observations underscore the need for standardized long-term endocrine follow-up and support the feasibility of larger, prospective studies to evaluate long-term neuropsychological outcome, especially in younger children.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1530\/eo-26-0010","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T10:49:26Z","timestamp":1779101366000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-15","source":"Crossref","is-referenced-by-count":0,"title":["Functional and behavioral outcomes in pediatric adrenal carcinoma under mitotane therapy: a caregiver-reported pilot study"],"prefix":"10.1530","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-0599-2824","authenticated-orcid":true,"given":"Heidi","family":"Frey","sequence":"first","affiliation":[{"name":"1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3273-1794","authenticated-orcid":true,"given":"Maria","family":"Riedmeier","sequence":"additional","affiliation":[{"name":"1"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Kr\u00fcger","sequence":"additional","affiliation":[{"name":"2"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carl Friedrich","family":"Classen","sequence":"additional","affiliation":[{"name":"3"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nerea","family":"Dom\u00ednguez-Pinilla","sequence":"additional","affiliation":[{"name":"4"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Fragoso","sequence":"additional","affiliation":[{"name":"5"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steffen","family":"Fuchs","sequence":"additional","affiliation":[{"name":"6"},{"name":"7"},{"name":"8"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominika","family":"Janus","sequence":"additional","affiliation":[{"name":"9"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mouna","family":"Mezoued","sequence":"additional","affiliation":[{"name":"10"},{"name":"11"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Mocna","sequence":"additional","affiliation":[{"name":"12"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Munarin","sequence":"additional","affiliation":[{"name":"13"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soraya","family":"Puglisi","sequence":"additional","affiliation":[{"name":"14"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hilal","family":"Susam Sen","sequence":"additional","affiliation":[{"name":"15"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerdi","family":"Tuli","sequence":"additional","affiliation":[{"name":"16"},{"name":"17"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justyna","family":"Walenciak","sequence":"additional","affiliation":[{"name":"18"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bilgehan","family":"Yalcin","sequence":"additional","affiliation":[{"name":"15"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Fassnacht","sequence":"additional","affiliation":[{"name":"19"},{"name":"20"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Verena","family":"Wiegering","sequence":"additional","affiliation":[{"name":"1"},{"name":"2"},{"name":"20"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"key":"2026070714150517300_bib1","doi-asserted-by":"crossref","first-page":"81","DOI":"10.5114\/pedm.2024.139271","article-title":"Adrenal cortical carcinoma: paediatric aspects \u2013 literature review","volume":"30","author":"Dasiewicz","year":"2024","journal-title":"Pediatr Endocrinol Diabetes Metab"},{"key":"2026070714150517300_bib2","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.jpedsurg.2013.02.017","article-title":"Predictors of survival in pediatric adrenocortical carcinoma: a surveillance, epidemiology, and end results (SEER) program study","volume":"48","author":"McAteer","year":"2013","journal-title":"J Pediatr Surg"},{"key":"2026070714150517300_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2020.101448","article-title":"Pediatric adrenocortical tumours","volume":"34","author":"Pinto","year":"2020","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"2026070714150517300_bib4","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.961650","article-title":"Pediatric adrenocortical carcinoma","volume":"13","author":"Ilanchezhian","year":"2022","journal-title":"Front Endocrinol"},{"key":"2026070714150517300_bib5","doi-asserted-by":"crossref","first-page":"5266","DOI":"10.3390\/cancers13215266","article-title":"Adrenocortical carcinoma in childhood: a systematic review","volume":"13","author":"Riedmeier","year":"2021","journal-title":"Cancers"},{"key":"2026070714150517300_bib6","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1515\/jpem.2011.175","article-title":"Clinical characteristics of adrenocortical tumors in children","volume":"24","author":"Chen","year":"2011","journal-title":"J Pediatr Endocrinol Metab"},{"key":"2026070714150517300_bib7","doi-asserted-by":"crossref","first-page":"G15","DOI":"10.1093\/ejendo\/lvae038","article-title":"International consensus on mitotane treatment in pediatric patients with adrenal cortical tumors: indications, therapy, and management of adverse effects","volume":"190","author":"Riedmeier","year":"2024","journal-title":"Eur J Endocrinol"},{"key":"2026070714150517300_bib8","doi-asserted-by":"crossref","first-page":"2463","DOI":"10.1200\/JCO.20.02871","article-title":"Treatment of pediatric adrenocortical carcinoma with surgery, retroperitoneal lymph node dissection, and chemotherapy: the children\u2019s oncology group ARAR0332 protocol","volume":"39","author":"Rodriguez-Galindo","year":"2021","journal-title":"J Clin Oncol"},{"key":"2026070714150517300_bib9","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.29025","article-title":"Adrenocortical tumours in children and adolescents: the EXPeRT\/PARTNER diagnostic and therapeutic recommendations","volume":"68","author":"Virgone","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"2026070714150517300_bib10","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1111\/bcp.14721","article-title":"Pharmacological profile and effects of mitotane in adrenocortical carcinoma","volume":"87","author":"Corso","year":"2021","journal-title":"Br J Clin Pharmacol"},{"key":"2026070714150517300_bib11","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1093\/oncolo\/oyae084","article-title":"A review of mitotane in the management of adrenocortical cancer","volume":"29","author":"Del Rivero","year":"2024","journal-title":"Oncologist"},{"key":"2026070714150517300_bib12","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1222002","article-title":"Neurological adverse events of mitotane in adrenocortical carcinoma: results of a pilot study","volume":"13","author":"Mormando","year":"2023","journal-title":"Front Oncol"},{"key":"2026070714150517300_bib13","doi-asserted-by":"crossref","first-page":"4452","DOI":"10.1210\/jc.2001-011978","article-title":"Long-term (15 years) outcome in an infant with metastatic adrenocortical carcinoma","volume":"87","author":"De Leon","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"2026070714150517300_bib14","doi-asserted-by":"crossref","first-page":"4061","DOI":"10.3390\/cancers16234061","article-title":"A review on mitotane: a target therapy in adrenocortical carcinoma","volume":"16","author":"Flauto","year":"2024","journal-title":"Cancers"},{"key":"2026070714150517300_bib15","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1530\/ERC-22-0146","article-title":"Key factors for effective mitotane therapy in children with adrenocortical carcinoma","volume":"29","author":"Kuhlen","year":"2022","journal-title":"Endocr Relat Cancer"},{"key":"2026070714150517300_bib16","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1136\/bmj.320.7244.1240","article-title":"Establishing a standard definition for child overweight and obesity worldwide: international survey","volume":"320","author":"Cole","year":"2000","journal-title":"BMJ"},{"key":"2026070714150517300_bib17","first-page":"48","volume-title":"Training Course on Child Growth Assessment, WHO Child Growth Standards.","author":"World Health Organization","year":"2008"},{"key":"2026070714150517300_bib18","doi-asserted-by":"crossref","first-page":"660","DOI":"10.2471\/BLT.07.043497","article-title":"Development of a WHO growth reference for school-aged children and adolescents","volume":"85","author":"de Onis","year":"2007","journal-title":"Bull World Health Organ"},{"key":"2026070714150517300_bib19","volume-title":"Body Mass Index-for-Age (BMI-for-Age)","author":"World Health Organization","year":"2006"},{"key":"2026070714150517300_bib20","volume-title":"Growth Reference Data for 5\u201319 Years","author":"World Health Organization","year":"2007"},{"key":"2026070714150517300_bib21","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1093\/ije\/dyg099","article-title":"The World Health Organization Global Database on Child Growth and Malnutrition: methodology and applications","volume":"32","author":"De Onis","year":"2003","journal-title":"Int J Epidemiol"},{"key":"2026070714150517300_bib22","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1016\/S0140-6736(17)32129-3","article-title":"Worldwide trends in body-mass index, underweight, overweight, and obesity from 1975 to 2016: a pooled analysis of 2416 population-based measurement studies in 128.9 million children, adolescents, and adults","volume":"390","author":"NCD Risk Factor Collaboration (NCD-RisC)","year":"2017","journal-title":"Lancet"},{"key":"2026070714150517300_bib23","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/s12887-019-1495-6","article-title":"Measuring social participation in children with chronic health conditions: validation and reference values of the child and adolescent scale of participation (CASP) in the German context","volume":"19","author":"De Bock","year":"2019","journal-title":"BMC Pediatr"},{"key":"2026070714150517300_bib24","first-page":"8","volume-title":"The Child and Adolescent Scale of Participation (CASP)\u00a9 \u2013 Administration and Scoring Guidelines","author":"Bedell","year":"2011"},{"key":"2026070714150517300_bib25","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.3390\/ijerph18041625","article-title":"Participation restrictions among children and young adults with acquired brain injury in a pediatric outpatient rehabilitation cohort: the patients\u2019 and parents\u2019 perspective","volume":"18","author":"Allonsius","year":"2021","journal-title":"Int J Environ Res Public Health"},{"key":"2026070714150517300_bib26","doi-asserted-by":"crossref","DOI":"10.15220\/978-92-9189-123-8-en","volume-title":"International Standard Classification of Education, ISCED 2011","author":"UNESCO Institute for Statistics","year":"2012"},{"key":"2026070714150517300_bib27","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/j.1469-7610.1997.tb01545.x","article-title":"The strengths and difficulties questionnaire: a research note","volume":"38","author":"Goodman","year":"1997","journal-title":"J Child Psychol Psychiatry"},{"key":"2026070714150517300_bib28","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1097\/00004583-200111000-00015","article-title":"Psychometric properties of the strengths and difficulties questionnaire","volume":"40","author":"Goodman","year":"2001","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"2026070714150517300_bib29","doi-asserted-by":"crossref","first-page":"5001","DOI":"10.3390\/cancers13195001","article-title":"Metabolic and endocrine toxicities of mitotane: a systematic review","volume":"13","author":"Bianchini","year":"2021","journal-title":"Cancers"},{"key":"2026070714150517300_bib30","article-title":"A case report of neurological adverse events caused by short-term and low-dose treatment of mitotane: the role of therapeutic drug monitoring","volume":"99","author":"Liu","year":"2020","journal-title":"Medicine"},{"key":"2026070714150517300_bib31","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S2213-8587(24)00378-4","article-title":"Adrenocortical carcinoma: a practical guide for clinicians","volume":"13","author":"Fassnacht","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2026070714150517300_bib32","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.4158\/DSCR-2020-0567","article-title":"American association of clinical endocrinology disease state clinical review on the evaluation and management of adrenocortical carcinoma in an adult: a practical approach","volume":"26","author":"Kiseljak-Vassiliades","year":"2020","journal-title":"Endocr Pract"},{"key":"2026070714150517300_bib33","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/ejendo\/lvae007","article-title":"Recovery of adrenal function after stopping mitotane in patients with adrenocortical carcinoma","volume":"190","author":"Altieri","year":"2024","journal-title":"Eur J Endocrinol"},{"key":"2026070714150517300_bib34","doi-asserted-by":"crossref","first-page":"639","DOI":"10.3390\/cancers12030639","article-title":"Recovery of adrenal insufficiency is frequent after adjuvant mitotane therapy in patients with adrenocortical carcinoma","volume":"12","author":"Poirier","year":"2020","journal-title":"Cancers"},{"key":"2026070714150517300_bib35","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1515\/jpem-2025-0162","article-title":"Clinical spectrum, imaging characteristics, and treatment outcomes of pediatric adrenocortical tumors: a 24-year experience from Western India","volume":"38","author":"Daga","year":"2025","journal-title":"J Pediatr Endocrinol Metab"},{"key":"2026070714150517300_bib37","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1001\/jama.2025.22234","article-title":"Sibling comparisons to account for confounding in observational studies","volume":"335","author":"Ahlqvist","year":"2026","journal-title":"JAMA"},{"key":"2026070714150517300_bib38","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1001\/jama.2016.6967","article-title":"Association between a single general anesthesia exposure before age 36 months and neurocognitive outcomes in later childhood","volume":"315","author":"Sun","year":"2016","journal-title":"JAMA"}],"container-title":["Endocrine Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eo.bioscientifica.com\/view\/journals\/eo\/6\/1\/EO-26-0010.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eo.bioscientifica.com\/downloadpdf\/journals\/eo\/6\/1\/EO-26-0010.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/eo\/article-pdf\/doi\/10.1530\/EO-26-0010\/520520\/eo-26-0010.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/journals.bioscientifica.com\/eo\/article-pdf\/doi\/10.1530\/EO-26-0010\/520520\/eo-26-0010.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T18:16:30Z","timestamp":1783448190000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.bioscientifica.com\/eo\/article\/6\/1\/e260010\/77652\/Functional-and-behavioral-outcomes-in-pediatric"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,1]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,1]]}},"URL":"https:\/\/doi.org\/10.1530\/eo-26-0010","relation":{},"ISSN":["2634-4793"],"issn-type":[{"value":"2634-4793","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,1]]},"article-number":"e260010"}}